Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for lung cancer, but not all patients benefit equally from these therapies. A study presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting examined the factors that drive ICI adoption specifically among urban patients with lung cancer, shedding light on which individuals are more likely to receive these drugs and why. Researchers reported that a combination of clinical, demographic, and healthcare system variables strongly influences whether a patient starts ICI therapy.

Key Takeaways

  • Older age and higher comorbidity burden were associated with lower ICI adoption rates in urban lung cancer patients.
  • Patients with private insurance or Medicare were significantly more likely to receive ICIs than those on Medicaid or uninsured.
  • Access to a large academic medical center or a dedicated cancer center strongly predicted ICI use.
  • Race and ethnicity remained independent predictors, with Black and Hispanic patients receiving ICIs less often than white patients, even after adjusting for other factors.
  • Earlier stage at diagnosis and better performance status (ECOG 0-1) correlated with higher ICI adoption.

Understanding ICI Adoption in Urban Settings

Urban cancer patients often have better geographic access to specialized oncology care than rural counterparts, yet significant disparities persist within cities. The ASCO 2026 study aimed to identify which specific characteristics most strongly predict whether an urban patient with lung cancer will receive an ICI. The researchers analyzed data from multiple urban hospitals and cancer registries, focusing on patients diagnosed with advanced non-small cell lung cancer (NSCLC) in the years following the approval of first-line ICIs.

According to the presentation, the adoption rate of ICIs among eligible urban patients remained below 60%, indicating that many who could benefit from these drugs do not receive them. This gap is not fully explained by clinical contraindications, suggesting that nonclinical factors play a major role.

Clinical Factors and Patient Characteristics

The study found that patient age and overall health status were strong predictors. Patients older than 75 years were about 30% less likely to receive an ICI compared with those aged 55 to 64. Similarly, individuals with a higher number of comorbid conditions, such as heart disease or diabetes, had lower odds of ICI initiation. Performance status, a measure of daily living ability, also mattered: patients with an ECOG score of 2 or higher were significantly less likely to be prescribed an ICI.

On the other hand, tumor characteristics such as PD-L1 expression level and histology (squamous versus nonsquamous) did not emerge as strong independent drivers of ICI adoption in the analysis, although they typically guide clinical decision making. This suggests that patient and system factors may sometimes override biomarker-based indications.

Socioeconomic and Racial Disparities

Socioeconomic status and race were both independently associated with ICI adoption. Patients with private insurance or Medicare were roughly twice as likely to receive an ICI as those covered by Medicaid or without any insurance. Income level and education also correlated with treatment receipt, though the study authors cautioned that these variables are closely linked to insurance type.

Race and ethnicity remained significant after adjusting for insurance and other covariates. Black patients had a 20% lower probability of ICI initiation, and Hispanic patients a 15% lower probability, compared with non-Hispanic white patients. The researchers pointed to potential biases in referral patterns, provider communication, and patient trust as possible explanations that warrant further investigation.

Healthcare System and Access Factors

The type of hospital where a patient received care was one of the strongest predictors of ICI adoption. Patients treated at a National Cancer Institute (NCI) designated cancer center or at a large academic medical center were much more likely to receive ICIs than those treated at community hospitals, even when the latter were located in the same urban area. This gap may reflect differences in the availability of multidisciplinary tumor boards, clinical trial access, and specialist expertise.

Distance to the treating facility also mattered, though within urban settings the range was smaller than in rural studies. Patients living more than 10 miles from their oncology clinic had lower ICI adoption rates than those living closer. The authors suggested that transportation barriers and the need for frequent visits likely contribute to this finding.

Implications for Practice and Policy

The ASCO 2026 study highlights that even in cities, where resources are concentrated, equitable access to innovative cancer therapies like ICIs is not guaranteed. The findings underscore the importance of addressing nonclinical barriers such as insurance coverage, race related disparities, and hospital referral networks. Interventions could include patient navigation programs, telemedicine for follow up visits, and educational outreach to community oncologists.

For clinicians discussing treatment options with lung cancer patients, the study serves as a reminder that decisions about ICI therapy should be guided by clinical evidence and patient preferences, not by unconscious biases or systemic obstacles. Future research should explore why race and socioeconomic status continue to influence ICI adoption and test strategies to eliminate these gaps.

Frequently Asked Questions

What are immune checkpoint inhibitors (ICIs)?

Immune checkpoint inhibitors are a class of immunotherapy drugs that block proteins such as PD-1 or PD-L1, allowing the immune system to recognize and attack cancer cells more effectively. They are commonly used to treat advanced lung cancer and have improved survival outcomes for many patients.

Why do some urban patients not receive ICIs even when eligible?

The study found that nonclinical factors like older age, multiple comorbidities, lack of private insurance, minority race or ethnicity, and receiving care at a community hospital rather than an academic center all reduce the likelihood of ICI adoption. These disparities persist even after accounting for medical eligibility.

How can healthcare providers improve ICI access for urban lung cancer patients?

Providers can use systematic screening to identify eligible patients, address insurance barriers through social work and financial counseling, implement culturally sensitive communication, and refer patients to high volume centers when appropriate. Reducing travel burdens via telemedicine or local infusion partnerships may also help.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.